Patent ID: 11857611
Assignee: GEOVAX, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A

Claim 0:
1. A recombinant modified vaccinia Ankara (MVA) viral vector comprising:
i) a first nucleic acid sequence encoding a Plasmodium falciparum immunogenic polypeptide comprising a circumsporozoite protein (CSP) with 21 asparagine (N)-alanine (A)-asparagine (N)-proline (P) (NANP) repeats (CSP21R),
ii) a second nucleic acid sequence encoding a Plasmodium falciparum immunogenic polypeptide comprising a gametocyte surface protein P230 (Pfs230), the Plasmodium falciparum immunogenic Pfs230 polypeptide further comprising a transmembrane domain of a glycoprotein (GP) of Marburg virus, and
iii) a third nucleic acid encoding a Marburg virus VP40 matrix protein;
wherein the first nucleic acid, the second nucleic acid sequence, and the third nucleic acid sequence are each under the control of a promoter compatible with poxvirus expression systems.